Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis

  • End date
    Sep 26, 2024
  • participants needed
  • sponsor
    University Hospital Tuebingen
Updated on 26 January 2021
pulmonary function test
chest ct
progressive systemic sclerosis
diffuse cutaneous systemic sclerosis


Autologous stem cell therapy has been shown to be effective in patients with systemic sclerosis. Nevertheless treatment is associated with treatment related mortality and patients die during follow up despite successful transplantation.

Intention of this trial is to improve overall survival by modifying the existing protocol used for the ASTIS trial.

To reduce treatment toxicity we reduce the dose of Cyclophosphamide (CYC) for mobilisation to 2x1g.

Especially in patients with cardiac manifestations we also modify the conditioning regimen by adding thiotepa and reducing CYC; as CYC has known cardiotoxic side effects.

Condition Scleroderma, Systemic sclerosis, Cardiac Involvement, Autologous Stem Cell Transplantation, Autologous Hematopoietic Stem Cell Transplantation, progressive systemic sclerosis
Treatment Autologous stemcell transplantation with CD (cluster of differentiation) 34 selected stem cells
Clinical Study IdentifierNCT01895244
SponsorUniversity Hospital Tuebingen
Last Modified on26 January 2021


Yes No Not Sure

Inclusion Criteria

Diagnosis of progressive systemic sclerosis <7 years
Progressive course despite cyclophosphamide pretreatment
Cyclophosphamide i.v.: at least 3 x with 500-1000 mg/m every 3-4 weeks or
Cyclophosphamide p.o. with at least 100mg/day for at least 2 months or
Contraindication to treatment with cyclophosphamide
Progress defined as at least one of the following criteria
Increase in the mRSS
Worsening of the lung function
Increase in fibrosis/alveolitis in thorax CT
Worsening kidney function through manifestation of systemic sclerosis
Limited or diffuse cutaneous progressive form of Ssc with organ manifestation in the lungs/heart or kidneys

Exclusion Criteria

Age <18 years
Pregnancy or inadequate contraception
Severe heart failure with ejection fraction (EF) < 30% in echo
Pulmonary arterial hypertension with systolic pulmonary arterial pressure (PAPsys) >50mm Hg
Kidney insufficiency: creatinine clearance <30 ml/min
Reduced lung function
Inspiratory vital capacity (IVC) < 50% of normal
Carbon monoxide (CO)-Diffusion capacity SB < 40%
Previously damaged bone marrow
Leukopenia < 2,000/l
Thrombopenia < 100,000/l
Previous myelotoxic treatment
Cyclophosphamide > 50g cumulative (relative)
Infection (Hepatitis B/C, HIV, Salmonella carrier, syphilis, relative: history of tuberculosis)
Severe concomitant psychiatric illness (depression, psychosis)
Substance dependence
Continued nicotine abuse
Continued alcohol abuse
Continued drug abuse
Consent not given
Poor compliance
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note